Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natesto PK Study in Hypogonadal Boys
NCT03345797Phase 1Terminated
- Sponsor
- Acerus Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of natesto in Hypogonadism (2 arms), sponsored by Acerus Pharmaceuticals. Primary endpoints: Maximum plasma concentration at 48 hours, Area under the curve at 48 hours and 2 more. Started Mar 2018; status: terminated.
02
Drugs
natesto
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT03345797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345797.